| These highlights do not include all the information needed to use WEZLANA™ safely and effectively. See full prescribing information for WEZLANA. WEZLANA™ (ustekinumab-auub) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2023 WEZLANA™ (ustekinumab-auub) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful | Nuvaila Limited | Amgen, Inc | 20260524 | 8 |
| These highlights do not include all the information needed to use Ustekinumab safely and effectively. See full prescribing information for USTEKINUMAB. Ustekinumab injection, for subcutaneous or intravenous use Initial U.S. Approval: 2009 | Janssen Biotech, Inc. | Cilag AG | Janssen Biologics B.V. | Baxter Pharmaceutical Solutions | Janssen Sciences Ireland UC | PPD Development Ireland Ltd. | 20260424 | 6 |
| These highlights do not include all the information needed to use STELARA safely and effectively. See full prescribing information for STELARA. STELARA ® (ustekinumab) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2009 | Janssen Biotech, Inc. | Janssen Biologics B.V. | Cilag AG | Simtra US LLC | PPD Development Ireland Ltd. | Janssen Sciences Ireland UC | 20260422 | 47 |
| These highlights do not include all the information needed to use STEQEYMA safely and effectively. See full prescribing information for STEQEYMA. STEQEYMA (ustekinumab-stba) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 STEQEYMA (ustekinumab-stba) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningf | CELLTRION USA, Inc. | CELLTRION Inc. | 20260407 | 12 |
| These highlights do not include all the information needed to use PYZCHIVA safely and effectively. See full prescribing information for PYZCHIVA. PYZCHIVA ® (ustekinumab-ttwe) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 PYZCHIVA (ustekinumab-ttwe) is biosimilar* to STELARA (ustekinumab). | SANDOZ INC | 20260313 | 16 |
| These highlights do not include all the information needed to use USTEKINUMAB-AAUZ safely and effectively. See full prescribing information for USTEKINUMAB-AAUZ. USTEKINUMAB-AAUZ injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 This product is OTULFI (ustekinumab-aauz). Ustekinumab-aauz is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and | Fresenius Kabi USA, LLC | 20260226 | 4 |
| These highlights do not include all the information needed to use USTEKINUMAB-AEKN safely and effectively. See full prescribing information for USTEKINUMAB-AEKN . USTEKINUMAB-AEKN injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 Ustekinumab-aekn is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful di | Teva Pharmaceuticals USA, Inc. | 20260225 | 6 |
| These highlights do not include all the information needed to use OTULFI safely and effectively. See full prescribing information for OTULFI. OTULFI (ustekinumab-aauz) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 OTULFI (ustekinumab-aauz) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful diffe | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | 20260216 | 4 |
| These highlights do not include all the information needed to use PYZCHIVA safely and effectively. See full prescribing information for PYZCHIVA. PYZCHIVA ® (ustekinumab-ttwe) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 PYZCHIVA (ustekinumab-ttwe) is biosimilar* to STELARA (ustekinumab). | Cordavis Limited | 20260206 | 6 |
| These highlights do not include all the information needed to use USTEKINUMAB-TTWE safely and effectively. See full prescribing information for USTEKINUMAB-TTWE. USTEKINUMAB-TTWE injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 Ustekinumab-ttwe is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful dif | Quallent Pharmaceuticals Health LLC | 20260112 | 6 |
| These highlights do not include all the information needed to use YESINTEK safely and effectively. See full prescribing information for YESINTEK. YESINTEK TM (ustekinumab-kfce) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 YESINTEK TM (ustekinumab-kfce) is biosimilar* to STELARA ® (ustekinumab). | Biocon Biologics Inc. | Biocon Biologics Limited | 20251209 | 9 |
| These highlights do not include all the information needed to use IMULDOSA safely and effectively. See full prescribing information for IMULDOSA. IMULDOSA (ustekinumab-srlf) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 IMULDOSA (ustekinumab-srlf) is biosimilar* to STELARA ® (ustekinumab) | Accord BioPharma Inc. | 20251203 | 9 |
| These highlights do not include all the information needed to use SELARSDI safely and effectively. See full prescribing information for SELARSDI. SELARSDI™ (ustekinumab-aekn) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 SELARSDI (ustekinumab-aekn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaning | Teva Pharmaceuticals USA, Inc. | 20251203 | 13 |
| These highlights do not include all the information needed to use USTEKINUMAB-AEKN safely and effectively. See full prescribing information for USTEKINUMAB-AEKN . USTEKINUMAB-AEKN injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 Ustekinumab-aekn is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful di | Teva Pharmaceuticals USA, Inc. | 20251203 | 9 |
| These highlights do not include all the information needed to use SELARSDI safely and effectively. See full prescribing information for SELARSDI. SELARSDI™ (ustekinumab-aekn) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 SELARSDI (ustekinumab-aekn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaning | A-S Medication Solutions | 20251120 | 1 |
| These highlights do not include all the information needed to use STARJEMZA™ safely and effectively. See full prescribing information for STARJEMZA™. STARJEMZA™ (ustekinumab-hmny) injection, for subcutaneous or intravenous use Initial U.S. Approval: 202 5 STARJEMZA™ (ustekinumab-hmny) is biosimilar* to STELARA ® (ustekinumab). | Hikma Pharmaceuticals USA Inc. | 20251024 | 5 |